Diamyd Medical receives Notice of Grant in Japan for insulin-based antigen therapy patent in type 1 diabetes

Diamyd Medical has received a Notice of Grant in Japan for a patent covering the use of insulin-based antigens to treat individuals with type 1 diabetes who carry the HLA DR4-DQ8 genetic marker. Once issued, the patent is expected to remain in force until 2038.Diamyd Medical holds granted precision medicine patents for treating and preventing type 1 diabetes in key global markets: · The newly granted Japanese patent for insulin-based antigen therapy targeting individuals with HLA DR4-DQ8 has corresponding patents granted in Europe, Eurasia, Hong Kong, and South Korea, with additional